{"id":2482,"date":"2023-04-26T16:48:13","date_gmt":"2023-04-26T13:48:13","guid":{"rendered":"https:\/\/tlab.com.tr\/?p=2482"},"modified":"2025-03-21T08:37:10","modified_gmt":"2025-03-21T05:37:10","slug":"treatment-of-resistant-chronic-central-serous-chorioretinopathy-via-platelet-rich-plasma-with-electromagnetic-stimulation","status":"publish","type":"post","link":"https:\/\/tlab.com.tr\/en\/treatment-of-resistant-chronic-central-serous-chorioretinopathy-via-platelet-rich-plasma-with-electromagnetic-stimulation\/","title":{"rendered":"Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation"},"content":{"rendered":"

To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR).<\/p>\n

The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively.
\nAt time 3, the mean bestcorrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively.<\/p>\n

Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electro-magnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR).
\nDesign: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receivingmicropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively.
\nResults: At time 3, the mean best-corrected visual acuity was 85.7 and 97 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively.
\nConclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option.<\/p>\n\n\n

\n
Click here to read<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR). The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively. At time 3, the mean bestcorrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively. Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electro-magnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR). Design: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receivingmicropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively. Results: At time 3, the mean best-corrected visual acuity was 85.7 and 97 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively. Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option.<\/p>","protected":false},"author":1,"featured_media":2491,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[58,94],"tags":[],"class_list":["post-2482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-akademik-makaleler","category-ophthalmology"],"views":75,"_links":{"self":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/2482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/comments?post=2482"}],"version-history":[{"count":2,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/2482\/revisions"}],"predecessor-version":[{"id":9824,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/posts\/2482\/revisions\/9824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/media\/2491"}],"wp:attachment":[{"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/media?parent=2482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/categories?post=2482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tlab.com.tr\/en\/wp-json\/wp\/v2\/tags?post=2482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}